Clinical trials: Patients With Diabetes.
Diabetic Foot, Chronic Ulcer
Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs
The study is a multi-center, prospective, randomized, controlled, single blinded clinical study consisting of 150 subjects from up to 20 centers.
- Trial name
- NCT04185558
- Testing
- ActiGraft, Standard of Care
- Where
- 16 sites in United States, South Africa and 1 more
- Volunteers
- 119 people
- Sponsor
- RedDress Ltd.
Diabetic Nephropathy
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety…
- Trial name
- NCT00044148
- Testing
- LY333531
- Where
- 15 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chromaderm, Inc.
Dyslipidemia, Glucose Metabolism Disorder
Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI
Under conditions of first-line drug treatment in antidiabetic drug naïve/drug free patients with type 2 diabetes mellitus and dyslipidemia, to show that :- the efficacy of a fixed combination (FC) of fenofibrate and metformin on…
- Trial name
- NCT00361868
- Testing
- fenofibrate (F) + metformin (M) hydrochloride fixed combination, Rosiglitazone
- Where
- 70 sites in Croatia, Finland and 6 more
- Volunteers
- 88 people
- Sponsor
- Solvay Pharmaceuticals
Glucose Lowering
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
To assess the pharmacokinetics of AZD1656, and its metabolite, in type 2 diabetes mellitus patients with varying degrees of renal impairment and to compare the results with those in patients with normal renal function.
- Trial name
- NCT01069926
- Testing
- AZD1656
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
Primary Objective: To demonstrate that the simple daily titration algorithm is non-inferior to the weekly titration algorithm according to Canadian labeling.
- Trial name
- LixilanOne CAN (NCT03767543)
- Testing
- INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
- Where
- 32 sites in Canada
- Volunteers
- 265 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
- Trial name
- NCT00621140
- Testing
- linagliptin
- Where
- 69 sites in Croatia, India and 9 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
Primary Objective: To demonstrate the superiority of glimepiride and metformin free combination in comparison to glimepiride or metformin alone in terms of Hb1Ac reduction during a 24-week treatment period in patients with type 2…
- Trial name
- RECOMMEND (NCT01459809)
- Testing
- GLIMEPIRIDE, METFORMIN
- Where
- 55 sites in Algeria, Colombia and 12 more
- Volunteers
- 538 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus
This protocol is intended to compare the effects of both a solid (tablet) and liquid oral dosage form of LX4211 in subjects with type 2 diabetes mellitus.
- Trial name
- NCT01188863
- Testing
- 300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and glimepiride as monotherapy
- Trial name
- NCT00363519
- Testing
- Sitagliptin phosphate
- Where
- 8 sites in Japan
- Volunteers
- 195 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Diabetic Neuropathies
ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy
To demonstrate the superiority of ASP8825 over placebo and dose response in patients with painful diabetic polyneuropathy.
- Trial name
- NCT00508430
- Testing
- ASP8825
- Where
- 8 sites in Japan
- Volunteers
- 199 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients
The aim of this study is to evaluate the efficacy and safety fo CJ-30001/CJ-30002.
- Trial name
- NCT01370707
- Testing
- Metformin, CJ-30001/CJ-30002
- Where
- 21 sites in South Korea
- Volunteers
- 187 people
- Sponsor
- HK inno.N Corporation
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in…
- Trial name
- NCT00099944
- Testing
- vildagliptin, Glimepiride
- Where
- United States
- Volunteers
- 515 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Type 2
A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients
DM199 (recombinant human tissue kallikrein-1) is a new investigational compound that may eventually be used for the treatment of Diabetes Mellitus Type 2. This is the first time that this compound is being given to humans.
- Trial name
- NCT01845064
- Testing
- DM199
- Where
- Netherlands
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- DiaMedica Therapeutics Inc
Type 2 Diabetes Mellitus
Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy
The purpose of this study is to assess the efficacy and safety of vildagliptin 50 mg bid compared to placebo as an add-on therapy to metformin in Chinese patients with T2DM inadequately controlled by metformin alone.
- Trial name
- NCT00822211
- Testing
- Vildagliptin 50 mg bid, Vildagliptin 50 mg qd
- Where
- 17 sites in China
- Volunteers
- 404 people
- Sponsor
- Novartis
Type 2 Diabetes
A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes
The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.
- Trial name
- NCT00871936
- Testing
- SLx-4090, Metformin
- Where
- 12 sites in United States
- Volunteers
- 82 people
- Sponsor
- Response Pharmaceuticals
Diabetes Mellitus, Type 2
Lantus Effect on Myocardial Glucose Metabolism in T2
The primary objective of the present study is to assess changes of myocardial glucose uptake (MGU) during clamp studies using positron emission tomography (PET) scanning in patients with type 2 diabetes and idiopathic left…
- Trial name
- NCT00335465
- Testing
- Insulin glargine
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
Primary Objective: To demonstrate noninferiority of Toujeo versus "standard of care" basal insulin therapy as measured by glycated hemoglobin (HbA1c) change Secondary Objectives: To demonstrate superiority of Toujeo versus…
- Trial name
- REGAIN CONTROL (NCT02967211)
- Testing
- insulin glargine (U300), insulin glargine (U100), NPH insulin
- Where
- 118 sites in Brazil, Finland and 8 more
- Volunteers
- 609 people
- Sponsor
- Sanofi
Dyslipidemia Associated With Type II Diabetes Mellitus
An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes
This study investigated the effectiveness of pravastatin on renal function in Korean dyslipidemic patients with Type 2 diabetes.
- Trial name
- NCT05107063
- Testing
- Pravastatin
- Where
- 47 sites in South Korea
- Volunteers
- 2,972 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Primary Objective: To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 Diabetes.
- Trial name
- LIXILAN JP-O2 (NCT02752828)
- Testing
- Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Oral anti-diabetic drugs
- Where
- 113 sites in Japan
- Volunteers
- 521 people
- Sponsor
- Sanofi
Diabetic Foot
Study of Subjects With Diabetic Foot Ulcer (DFU)
Foot ulceration is a common and costly complication of diabetes. GSK1278863 is a topical drug, which is being developed to treat wounds associated with DFU.
- Trial name
- NCT03153007
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline